Utilizing 3D Models to Unravel the Dynamics of Myeloma Plasma Cells' Escape from the Bone Marrow Microenvironment

被引:2
作者
Verbruggen, Stefaan W. [1 ,2 ,3 ]
Freeman, Ciara L. [4 ]
Freeman, Fiona E. [5 ,6 ,7 ,8 ,9 ,10 ]
机构
[1] Queen Mary Univ London, Digital Environm Res Inst, London E1 1HH, England
[2] Queen Mary Univ London, Ctr Predict In Vitro Models, Sch Engn & Mat Sci, London E1 4NS, England
[3] Univ Sheffield, INSIGNEO Inst In Silico Med, Sheffield S1 3JD, England
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[5] Univ Coll Dublin, Engn & Mat Sci Ctr, Sch Mech & Mat Engn, Dublin D04 V1W8, Ireland
[6] Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dublin D04 V1W8, Ireland
[7] Trinity Coll Dublin, Trinity Biomed Sci Inst, Trinity Ctr Biomed Engn, Dublin D02 PN40, Ireland
[8] Trinity Coll Dublin, Sch Engn, Dept Mech Mfg & Biomed Engn, Dublin D02 PN40, Ireland
[9] Royal Coll Surgeons Ireland, Adv Mat & Bioengn Res Ctr AMBER, Dublin D02YN77, Ireland
[10] Trinity Coll Dublin, Dublin D02YN77, Ireland
基金
英国工程与自然科学研究理事会;
关键词
multiple myeloma; biological models; bone marrow; 3D printing; microfluidic devices; organ-on-a-chip; MULTIPLE-MYELOMA; IN-VITRO; IMPACT; CHEMOSENSITIVITY; RESISTANCE; RESPONSES; THERAPY; DISEASE; ASSAY;
D O I
10.3390/cancers16050889
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary New treatments have made a big difference in helping people with multiple myeloma (MM) live longer. In fact, survival rates have almost doubled compared with treatments before 2000, thanks to these new and effective medications. This means more people with MM are surviving for more than 10 years after being diagnosed. However, because people are living longer, some unusual situations are arising, like cancer coming back in places outside the bone marrow, such as organs, lymph nodes, and even the central nervous system. To better understand and treat these new challenges, scientists are using advanced 3D models, especially looking at the bone marrow and other places where cancer may show up. This review identifies the best ways to use these 3D models, discusses the difficulties in recreating the complexity of the disease, and emphasizes how these advanced models can help fight MM.Abstract Recent therapeutic advancements have markedly increased the survival rates of individuals with multiple myeloma (MM), doubling survival compared to pre-2000 estimates. This progress, driven by highly effective novel agents, suggests a growing population of MM survivors exceeding the 10-year mark post-diagnosis. However, contemporary clinical observations indicate potential trends toward more aggressive relapse phenotypes, characterized by extramedullary disease and dominant proliferative clones, despite these highly effective treatments. To build upon these advances, it is crucial to develop models of MM evolution, particularly focusing on understanding the biological mechanisms behind its development outside the bone marrow. This comprehensive understanding is essential to devising innovative treatment strategies. This review emphasizes the role of 3D models, specifically addressing the bone marrow microenvironment and development of extramedullary sites. It explores the current state-of-the-art in MM modelling, highlighting challenges in replicating the disease's complexity. Recognizing the unique demand for accurate models, the discussion underscores the potential impact of these advanced 3D models on understanding and combating this heterogeneous and still incurable disease.
引用
收藏
页数:19
相关论文
共 98 条
  • [1] Comprehensive small RNA-sequencing of primary myeloma cells identifies miR-105-5p as a predictor of patient survival
    Aass, Kristin Roseth
    Nedal, Tonje Marie Vikene
    Bouma, Siri Anshushaug
    Tryggestad, Synne Stokke
    Haukas, Einar
    Slordahl, Tobias Schmidt
    Waage, Anders
    Standal, Therese
    Mjelle, Robin
    [J]. BRITISH JOURNAL OF CANCER, 2023, 128 (04) : 656 - 664
  • [2] [Anonymous], Surveillance, Epidemiology
  • [3] Extramedullary disease in multiple myeloma
    Bansal, Radhika
    Rakshit, Sagar
    Kumar, Shaji
    [J]. BLOOD CANCER JOURNAL, 2021, 11 (09)
  • [4] A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome
    Beksac, Meral
    Seval, Guldane Cengiz
    Kanellias, Nicholas
    Coriu, Daniel
    Rosinol, Laura
    Ozet, Gulsum
    Goranova-Marinova, Vesselina
    Unal, Ali
    Bila, Jelena
    Ozsan, Hayri
    Ivanaj, Arben
    Balic, Lejla Ibricevic
    Kastritis, Efstathios
    Blade, Joan
    Dimopoulos, Meletios Athanasios
    [J]. HAEMATOLOGICA, 2020, 105 (01) : 201 - 208
  • [5] Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment
    Belloni, Daniela
    Heltai, Silvia
    Ponzoni, Maurilio
    Villa, Antonello
    Vergani, Barbara
    Pecciarini, Lorenza
    Marcatti, Magda
    Girlanda, Stefania
    Tonon, Giovanni
    Ciceri, Fabio
    Caligaris-Cappio, Federico
    Ferrarini, Marina
    Ferrero, Elisabetta
    [J]. HAEMATOLOGICA, 2018, 103 (04) : 707 - 716
  • [6] Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
    Berdeja, Jesus G.
    Madduri, Deepu
    Usmani, Saad Z.
    Jakubowiak, Andrzej
    Agha, Mounzer
    Cohen, Adam D.
    Stewart, A. Keith
    Hari, Parameswaran
    Htut, Myo
    Lesokhin, Alexander
    Deol, Abhinav
    Munshi, Nikhil C.
    O'Donnell, Elizabeth
    Avigan, David
    Singh, Indrajeet
    Zudaire, Enrique
    Yeh, Tzu-Min
    Allred, Alicia J.
    Olyslager, Yunsi
    Banerjee, Arnob
    Jackson, Carolyn C.
    Goldberg, Jenna D.
    Schecter, Jordan M.
    Deraedt, William
    Zhuang, Sen Hong
    Infante, Jeffrey
    Geng, Dong
    Wu, Xiaoling
    Carrasco-Alfonso, Marlene J.
    Akram, Muhammad
    Hossain, Farah
    Rizvi, Syed
    Fan, Frank
    Lin, Yi
    Martin, Thomas
    Jagannath, Sundar
    [J]. LANCET, 2021, 398 (10297) : 314 - 324
  • [7] Exosomal MiR-4261 mediates calcium overload in RBCs by downregulating the expression of ATP2B4 in multiple myeloma
    Bian, Sicheng
    Zhang, Xialin
    Lin, Leilei
    Sun, Lili
    Guo, Zhibo
    Pan, Jie
    Cui, Jiangxia
    Yao, Hanbing
    Xu, Jing
    Hao, Zhuanghui
    Wang, Yuzhu
    Tong, Liguo
    Bu, Xingpeng
    Kong, Desheng
    Liu, Nianjiao
    Li, Yinghua
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [8] Extramedullary disease in multiple myeloma: a systematic literature review
    Blade, Joan
    Beksac, Meral
    Caers, Jo
    Jurczyszyn, Artur
    Von Lilienfeld-Toal, Marie
    Moreau, Philippe
    Rasche, Leo
    Rosinol, Laura
    Usmani, Saad Z.
    Zamagni, Elena
    Richardson, Paul
    [J]. BLOOD CANCER JOURNAL, 2022, 12 (03)
  • [9] Bou Zerdan Maroun, 2022, Int J Hematol Oncol, V11, pIJH39, DOI 10.2217/ijh-2021-0017
  • [10] Braham MVJ, 2018, TISSUE ENG PART C-ME, V24, P300, DOI [10.1089/ten.tec.2017.0467, 10.1089/ten.TEC.2017.0467]